CorVent Medical, a Coridea portfolio company developing versatile, reusable, life-saving ventilators, announced that the US Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) for primary use of the ventilator RESPOND-19 ™ has granted the company in critical care. RESPOND-19 represents a new category of ventilator and is designed to rapidly expand ventilation capacity in intensive care units so that hospitals can treat more patients with acute respiratory distress syndrome in times of greatest emergency. The support system for surges in demand is optimized for long-term storage and ensures cost-effective preparation of medical care.USA available. The company also expects CE marking in early 2021.

“Like many other healthcare professionals, I experienced the first wave of COVID-19 cases and the resulting increase in the ventilation support required for patients. When demand exceeds supply of ventilators, healthcare providers must be able to scale resources quickly, safely and financially responsibly, "said Dr. Patrick Troy , pulmonologist at Hartford Hospital in Hartford, CT and chief medical officer of CorVent Medical. In the future, successful healthcare disaster preparedness will inevitably include reliable surgical ventilators that can be deployed when needed to meet growing patient needs.

The CorVent RESPOND-19 ventilator complements existing ventilation capabilities by providing primary intensive care for multiple patient use in one cost-effective device. The intuitive system combines sophisticated ventilation functions with a plug-and-play facility to streamline patient care management. In addition, the system's multi-level antiviral filters provide excellent infection control to protect both patients and healthcare professionals. The reliable system is optimized for maintenance-free long-term storage and makes costly service contracts for ventilation systems in intensive care units superfluous. COVID-19 has changed the market and RESPOND-19 aims to

“Current intensive care ventilators are not designed for periodic use, such as B. in global pandemics or in disaster management. They require expensive maintenance and additional time to use with long-term storage, and are not optimized to prevent the transmission of respiratory diseases, "commented Richard S. Walsh, CEO of CorVent Medical. “Our team's expertise in ventilator development and proven track record in bringing innovative products to market enables us to successfully address this urgent clinical need. We are proud that the RESPOND-19 ventilator can expand access to life-saving ventilation support in a financially sustainable manner for hospitals and government agencies during this healthcare crisis and beyond. "

This announcement is based on the company's latest announcement of a $ 4.5 million seed funding round to fund the commercialization of the company's first ventilator. The round was led by prominent European life science venture capital firm Sofinnova Partners,  with the participation of The Deerfield Foundation , Exor Seeds , Genesis Medtech Group , Redmile Group, The Pagliuca Family Office and Accel founder Jim Swartz .

About CorVent Medical, Inc.

CorVent Medical, a private portfolio company of the medical technology incubator Coridea LLC, is committed to developing intelligent, versatile, life-saving ventilators for critical care. The company's first product, the RESPOND-19 ™ ventilator, provides life-saving ventilation support designed to be reliable and affordable for use during surges and distress. The streamlined system is optimized for multi-patient use and enables sophisticated ventilation with excellent infection control. The RESPOND-19 ventilator recently received FDA Emergency Use Authorization (EUA) and is currently available for commercial use. More information about CorVent Medical can be found at www.corventmedical.com .

 

Source: prnewswire.com

Report Abuse